Tarveda Therapeutics Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Out of Business

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Liquidation

Tarveda Therapeutics General Information

Description

Developer of pentarin miniature drug conjugate medicines intended to make a difference in the treatment of patients with solid tumor malignancies. The company's platform provides a lead drug candidate that releases its potent topoisomerase 1 inhibitor payload, SN38 and it also develops a miniature drug conjugate in clinical evaluation for the treatment of patients with somatostatin receptor 2 expressing neuroendocrine, small cell lung, and other solid tumors, enabling companies to extend the lives of patients with hard to treat cancers while minimizing potential toxicities.

Contact Information

Formerly Known As
Blend Biosciences, Blend Therapeutics
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 134 Coolidge Avenue
  • Watertown, MA 02472
  • United States
+1 (617)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 134 Coolidge Avenue
  • Watertown, MA 02472
  • United States
+1 (617)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Tarveda Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Bankruptcy: Liquidation 07-Apr-2022 Completed Bankruptcy: Liquidation
11. Later Stage VC 27-Sep-2021 Completed Clinical Trials - Phase 2
10. Secondary Transaction - Private 01-Mar-2021 Completed Clinical Trials - Phase 2
9. Later Stage VC (Series 2) 28-Dec-2020 Completed Clinical Trials - Phase 2
8. Reverse Merger 07-Apr-2020 Cancelled Clinical Trials - Phase 2
7. Later Stage VC (Series 1) 26-Dec-2019 Completed Clinical Trials - Phase 2
6. Debt - General 29-Mar-2019 Completed Clinical Trials - Phase 2
5. Later Stage VC (Series D) 02-Feb-2017 Completed Clinical Trials - Phase 2
4. Later Stage VC (Series C) 01-Dec-2016 $25.5M $50.3M Completed Clinical Trials - Phase 2
3. Early Stage VC (Series B1) 11-Mar-2014 $1000K $24.8M Completed Clinical Trials - Phase 2
To view Tarveda Therapeutics’s complete valuation and funding history, request access »

Tarveda Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series 2
Series CS
Series 1
Series DD
Series CC
Series BB 1,443,330 $0.000100 $0.12 $2.04 $2.04 1x $2.04 0.66%
Series AA 189,499 $0.000100 $0.09 $1.58 $1.58 1x $1.58 0.09%
To view Tarveda Therapeutics’s complete cap table history, request access »

Tarveda Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of pentarin miniature drug conjugate medicines intended to make a difference in the treatment of patients with
Drug Discovery
Watertown, MA
6 As of 2023

Gaithersburg, MD
 

Gothenburg, Sweden
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Tarveda Therapeutics Competitors (18)

One of Tarveda Therapeutics’s 18 competitors is Altimmune, a Formerly VC-backed company based in Gaithersburg, MD.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Altimmune Formerly VC-backed Gaithersburg, MD
Toleranzia Private Equity-Backed Gothenburg, Sweden
ONL Therapeutics Venture Capital-Backed Ann Arbor, MI
Seagen Formerly VC-backed Bothell, WA
Intellia Therapeutics Formerly VC-backed Cambridge, MA
You’re viewing 5 of 18 competitors. Get the full list »

Tarveda Therapeutics Patents

Tarveda Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2022047008-A1 Hsp90-binding conjugates and formulations thereof Inactive 26-Aug-2020
WO-2021202830-A2 Hsp90-binding conjugates and formulations thereof Inactive 01-Apr-2020
WO-2021202830-A3 Hsp90-binding conjugates and formulations thereof Inactive 01-Apr-2020
JP-2022540317-A Hsp90 binding conjugates and their combination therapy Pending 25-Jun-2019
WO-2020263907-A1 Hsp90-binding conjugates and combination therapies thereof Inactive 25-Jun-2019 A61K47/552
To view Tarveda Therapeutics’s complete patent history, request access »

Tarveda Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Tarveda Therapeutics FAQs

  • When was Tarveda Therapeutics founded?

    Tarveda Therapeutics was founded in 2011.

  • Where is Tarveda Therapeutics headquartered?

    Tarveda Therapeutics is headquartered in Watertown, MA.

  • What is the size of Tarveda Therapeutics?

    Tarveda Therapeutics has 6 total employees.

  • What industry is Tarveda Therapeutics in?

    Tarveda Therapeutics’s primary industry is Drug Discovery.

  • Is Tarveda Therapeutics a private or public company?

    Tarveda Therapeutics is a Private company.

  • What is Tarveda Therapeutics’s current revenue?

    The current revenue for Tarveda Therapeutics is .

  • How much funding has Tarveda Therapeutics raised over time?

    Tarveda Therapeutics has raised $130M.

  • Who are Tarveda Therapeutics’s competitors?

    Altimmune, Toleranzia, ONL Therapeutics, Seagen, and Intellia Therapeutics are some of the 18 competitors of Tarveda Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process